Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | IL1B | P01584 | 4/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | TNF | P01375 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25316216 | 1.00 | AR (0.37) | ARIL1BCNR2LRRK2TNF | |
| SCHEMBL30507063 | 0.86 | AR (0.40) | ARIL1BCNR2LRRK2TNF | |
| SCHEMBL25924822 | 0.86 | AR (0.40) | ARIL1BCNR2LRRK2TNF | |
| SCHEMBL25313086 | 0.86 | AR (0.40) | ARIL1BCNR2LRRK2TNF | |
| SCHEMBL31349629 | 0.84 | CNR2 (0.34) | CNR2 | |
| SCHEMBL31349573 | 0.80 | AR (0.32) | AR | |
| SCHEMBL30506880 | 0.80 | FFAR1 (0.33) | ARIL1B | |
| SCHEMBL25317411 | 0.80 | FFAR1 (0.33) | ARIL1B | |
| SCHEMBL26023959 | 0.80 | FFAR1 (0.33) | ARIL1B | |
| SCHEMBL26023953 | 0.79 | ACACB (0.33) | ARIL1BCNR2LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | AR 3017/4885IL1B 1382/4885CNR2 4102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.